Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Aquapharm Bio-Discovery Ltd completes £1.25M funding and is first to locate in the new European Centre for Marine Biotechnology

11.08.2005


Aquapharm Bio – Discovery Ltd (Aquapharm), a leading UK marine biotechnology company developing, amongst other things, anti-infective drug candidates from marine natural products, is pleased to announce the completion this month of its latest round of financing.

The investment of £344000 by E-Synergy Ltd and the Scottish Enterprise Co-Investment Fund completed the £1.25 million package by adding to a recent earlier investment of £350000 (£175,000 each) by NESTA (the National Endowment for Science, Technology and the Arts) and Argyll & the Islands Enterprise (AIE), and thereby paving the way for a future equity investment of £253,400 and grants of up to £300000 from AIE.

Aquapharm was formed in 2000 by Dr Andrew Mearns Spragg & Dr Kathryn Fraser, and is one of the first UK marine biotechnology companies. This funding round has allowed it to expand into new bespoke laboratory facilities within the European Centre for Marine Biotechnology (ECMB), which is situated beside the sea near Oban in Argyll. The Company currently employs a team of 9 full-time staff and has recently strengthened the management team with the addition of three new non-executive directors.



Dr Jo Oliver who through a previous association with SAMS has a knowledge of who is doing what in marine biotechnology, and Mr Colin Garvie, who has extensive financial and commercial experience gained over 25 years which included working with one of the UK’s largest Venture Capital firms, will join long standing non-ex chairman Dr Ron James who provides commercial and deal making support to the board. The incoming investor director, Dr John White, a successful entrepreneur in his own right and a member of E-Synergy’s angel syndicate, will fly his own light aircraft to the local airport to attend board meetings and brings in a wealth of commercial skills.

Dr Andrew Mearns Spragg, the CEO of Aquapharm said “Completing this investment will allow the Company to increase its research programmes including expansion of the project screening of novel marine organisms for new antibiotics. Already, a new anti-infective molecule has been identified that targets multi-drug resistant infections such as MRSA. There is a definite need for new types of antibiotics to combat bacterial infections that have become resistant to most of our available antibiotics” Aquapharm’s other research programmes are the development marine sources of functional foods & organic carotenoid pigments.

The Company also offers access to its growing collection of marine organisms, some of which are new to science, and most of which were collected from Scottish waters, some of the most prolific and cleanest of marine environments in the world, to pharmaceutical and biotech companies that have assays to screen for other drugs, industrial enzymes etc.

Lachie Beaton, a spokesman for AIE said “We are delighted that Aquapharm has completed its funding package.” The ECMB was established along side SAMS to foster commercial development of marine science and build on the world-class academic marine biology we have here. It fits with the objectives of the Smart Successful Scotland programme”. John White added, “We are happy to have made this investment. The work the Company is doing is exciting and we believe, in time, we will make a good return. It is the first investment we have done with the Scottish Co-Investment fund, but I hope it will not be the last.

Joseph Meaney | alfa
Further information:
http://www.aquapharm.co.uk

More articles from Ecology, The Environment and Conservation:

nachricht Successful calculation of human and natural influence on cloud formation
04.11.2016 | Goethe-Universität Frankfurt am Main

nachricht Invasive Insects Cost the World Billions Per Year
04.10.2016 | University of Adelaide

All articles from Ecology, The Environment and Conservation >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>